Skip to main content
Clinical Trials/ISRCTN39133303
ISRCTN39133303
Completed
Phase 3

A randomised controlled trial of sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction

iverpool Women's NHS Foundation Trust (UK)0 sites112 target enrollmentJuly 31, 2014

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
iverpool Women's NHS Foundation Trust (UK)
Enrollment
112
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Registry
who.int
Start Date
July 31, 2014
End Date
July 31, 2016
Last Updated
7 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
iverpool Women's NHS Foundation Trust (UK)

Eligibility Criteria

Inclusion Criteria

  • 1\. Women with singleton pregnancy and fetus diagnosed with severe, early onset intrauterine growth restriction (IUGR) between 22\+0 and 29\+6 weeks of gestation and clinical decision to manage pregnancy expectantly.
  • 2\. IUGR is defined as estimated fetal weight or abdominal circumference \<10th centile and absent or reversed end diastolic velocity Doppler in the umbilical artery.
  • 3\. 16 years of age or older
  • 4\. Consent to take part in the trial

Exclusion Criteria

  • 1\. Multiple pregnancy
  • 2\. Known or suspected structural or chromosomal fetal abnormality
  • 3\. Maternal illness (e.g., pre\-eclampsia) that is expected to require delivery for maternal reasons within the next 72 hours
  • 4\. Maternal wish not to have active management of the pregnancy, or to have pregnancy termination weeks
  • 5\. Inability to give informed consent
  • 6\. Cocaine use
  • 7\. Contraindication to sildenafil therapy, e.g., known maternal cardiac disease, left ventricular outflow tract obstruction, concomitant treatment with nitrates or previous allergy to sildenafil

Outcomes

Primary Outcomes

Not specified

Similar Trials